Project Grant K08AI193172

Award Date 7/7/25
Completion Date 6/30/30
Dollars Obligated $187K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
This federal Project Grant award of $791,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify molecular factors controlling chromatin organization and gene regulation in the malaria parasite Plasmodium falciparum. The research aims to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and sexual differentiation, with the goal...
This $153,056 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Washington University will support research to investigate heme homeostasis mechanisms in the malaria parasite Plasmodium falciparum. The research aims to identify parasite heme-binding proteins and assess their essentiality for parasite viability, as well as investigate the role of the heme detoxification protein PfHDP in parasite...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,116 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to develop novel 4-aminoquinoline compounds as therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest species of malaria parasite. The project aims to further develop a compound, MH02-060, that has shown enhanced metabolic stability and in vivo efficacy...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $633,218 to Washington University to conduct research on the function of the PFNCR1 cholesterol transporter protein in the malaria parasite. The research aims to characterize the mechanism of inhibition of PFNCR1 by new small molecule inhibitors, and to explore the components and interactions in the...
This Project Grant award of $375,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a research project to investigate the role of messenger ribonucleoprotein (mRNP) granules in regulating RNA metabolism and translation in the malaria parasite Plasmodium falciparum. The project aims to identify molecular markers for distinct mRNP types, determine their protein and mRNA compositions, and characterize their...
This $516,175 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the impact of pre-existing humoral immunity on hepatocyte death and its implications for malaria vaccine development. The grant, awarded to Seattle Children's Hospital's research institute, will fund a 2-year project exploring how non-neutralizing antibodies may promote apoptosis in...
The federal Project Grant award of $459,131, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to identify essential functions of the mitochondrion in malaria parasites. The goal is to uncover novel drug targets within the parasite mitochondrion that could lead to the development of new antimalarial treatments effective against both symptomatic and transmission stages of malaria...
The University of Georgia Research Foundation was awarded a $540,193 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The 12-month award, effective August 22, 2023, supports research to investigate the role of calcium-binding proteins and other secretory pathway components in the exocytosis of organelles critical for the invasion and egress of the malaria parasite Plasmodium falciparum...
The Project Grant award R01AI187153 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on identifying genetic factors associated with sexual stage development (gametocyte formation) in the malaria parasite Plasmodium falciparum. The $700,288 award, with a project period from Nov 2024 to Oct 2029, will fund a research project at the University of South Florida to perform...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $187,056 to The Children's Hospital of Philadelphia (CHOP) over a 5-year period ending June 30, 2030. The grant supports research aimed at determining the role of erythrocyte (red blood cell) glycolysis, a key metabolic pathway, in the lifecycle of the malaria parasite Plasmodium falciparum. The research objectives are to understand how disruptions to erythrocyte glycolysis impact the growth and susceptibility of the malaria parasite, with the goal of identifying potential new antimalarial targets and therapies. The project will involve both inhibition studies and gene editing techniques in erythrocytes to systematically evaluate the importance of this host metabolic pathway to the parasite's survival and development within red blood cells.

Generated 8/5/25, 5:26 AM